161 related articles for article (PubMed ID: 2191681)
21. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
22. Distinct signals are required for proliferation and lymphokine gene expression in murine T cell clones.
Heckford SE; Gelmann EP; Agnor CL; Jacobson S; Zinn S; Matis LA
J Immunol; 1986 Dec; 137(11):3652-63. PubMed ID: 3097128
[TBL] [Abstract][Full Text] [Related]
23. Protocol design for lymphokine testing in clinical studies of human cancer.
Lotze MT; Rosenberg SA
Lymphokine Res; 1986; 5 Suppl 1():S177-81. PubMed ID: 3784611
[TBL] [Abstract][Full Text] [Related]
24. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Vetto JT; Seipp CA; Simpson C
Surgery; 1986 Aug; 100(2):262-72. PubMed ID: 3526604
[TBL] [Abstract][Full Text] [Related]
25. Activation of lymphokine genes during stimulation of cloned T cells.
Herold KC; Lancki DW; Dunn DE; Arai K; Fitch FW
Eur J Immunol; 1986 Dec; 16(12):1533-8. PubMed ID: 3102245
[TBL] [Abstract][Full Text] [Related]
26. Reverse transcriptase-polymerase chain reaction amplification and partial sequence of T helper 1- and T helper 2-type lymphokine genes from the owl monkey (Aotus trivirgatus).
Bost KL; Hellner CF; Holton RH; Ratterree MS; Clements JD; Krogstad DJ; Kincy-Cain T
Am J Trop Med Hyg; 1997 Mar; 56(3):351-8. PubMed ID: 9129542
[TBL] [Abstract][Full Text] [Related]
27. Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.
Oldham RK; Thurman GB; Talmadge JE; Stevenson HC; Foon KA
Cancer; 1984 Dec; 54(11 Suppl):2795-806. PubMed ID: 6437660
[TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killer cells: in vitro and in vivo studies.
Mazumder A
Lymphokine Res; 1985; 4(3):215-20. PubMed ID: 3897730
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor as a target for cancer gene therapy.
Nguyen JT
Adv Exp Med Biol; 2000; 465():447-56. PubMed ID: 10810648
[No Abstract] [Full Text] [Related]
30. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
31. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.
Thompson CB; Lindsten T; Ledbetter JA; Kunkel SL; Young HA; Emerson SG; Leiden JM; June CH
Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1333-7. PubMed ID: 2465550
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy of cancer through restoration of tumor-suppressor functions?
Friedmann T
Cancer; 1992 Sep; 70(6 Suppl):1810-7. PubMed ID: 1516033
[TBL] [Abstract][Full Text] [Related]
33. Antibodies to guinea pig lymphokines. II. Suppression of delayed hypersensitivity reactions by a "second generation" goat antibody against guinea pig lymphokines.
Geczy CL; Geczy AF; De Weck AL
J Immunol; 1976 Jul; 117(1):66-72. PubMed ID: 1084371
[TBL] [Abstract][Full Text] [Related]
34. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
35. Reversible defect in antigen-induced lymphokine and gamma-interferon generation in cutaneous leishmaniasis.
Murray HW; Rubin BY; Carriero S; Acosta AM
J Immunol; 1984 Oct; 133(4):2250-4. PubMed ID: 6432909
[TBL] [Abstract][Full Text] [Related]
36. Lymphokines and cytokines as cancer treatment. Immunotherapy realized.
Borden EC; Sondel PM
Cancer; 1990 Feb; 65(3 Suppl):800-14. PubMed ID: 2406003
[TBL] [Abstract][Full Text] [Related]
37. In vitro immunization of human B lymphocytes. MAPPing of lymphokine specific mRNA and the effect of recombinant factors.
Simonsson AC; Larrick JW; Borrebaeck CA
Hum Antibodies Hybridomas; 1991 Jul; 2(3):148-54. PubMed ID: 1873504
[TBL] [Abstract][Full Text] [Related]
38. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
39. Adoptive cancer immunotherapy utilizing lymphokine activated killer cells and gamma interferon activated killer monocytes.
Lacerna LV; Stevenson GW; Stevenson HC
Pharmacol Ther; 1988; 38(3):453-65. PubMed ID: 3143128
[No Abstract] [Full Text] [Related]
40. Phase I clinical trial of MAF containing preparation of RPMI-1788 B-cell human lymphoblastoid lymphokine in advanced cancer patients.
Reynolds RD; Khojasteh A; Papermaster BW; McEntire JE
Lymphokine Res; 1986; 5 Suppl 1():S165-70. PubMed ID: 3537547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
